Alaunos shares surge 11.86% intraday after announcing $2.0 million registered direct offering.

Alaunos Therapeutics, Inc. (TCRT) surged 11.86% intraday following a Schedule 13D filing by PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (ELAB), disclosing a 5.09% stake in the company. The filing, reported as a 13D/G, indicated a significant institutional investment, signaling confidence in TCRT’s strategic direction. This development, coupled with the firm’s prior advocacy for a term sheet from a Wall Street bank, likely spurred investor optimism. While a concurrent $2.0 million registered direct offering could raise dilution concerns, the Schedule 13D’s emphasis on a material ownership stake appears to have overshadowed other factors, directly driving the sharp intraday rally.